Literature DB >> 31677093

Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.

Adriana G Ioachimescu1,2, Talin Handa3, Neevi Goswami4, Adlai L Pappy5, Emir Veledar6, Nelson M Oyesiku7,8.   

Abstract

PURPOSE: To evaluate the impact of gender and year at surgery on clinical presentation and postoperative outcomes in acromegaly.
METHODS: Retrospective review of patients operated between 1994 and 2016 to compare presentation and outcomes in groups defined by gender and year of surgery. Kaplan-Meier survival analyses with a composite endpoint (recurrence, reoperation, and radiation) were used for gender comparison and Youden indices for biochemical remission rates changes during study period.
RESULTS: Primary indications for evaluation were phenotype, neurological symptoms, incidentaloma, hypogonadism, and galactorrhea. At surgery, men (N = 54) were younger (43.6 ± 12.7 years) than women (N = 58, 48.7 ± 12.3, P = 0.04). Male:female ratios before and after age 50 were 1.4 and 0.6 respectively. Men had higher mean IGF-1 levels (874 ± 328 vs 716 ± 296, P < 0.01) and smaller tumors (1.8 ± 1.3 cm vs 2.3 ± 1.5, P = 0.04). Postoperative remission rates were comparable (51% men, 56% women) and inversely associated with cavernous sinus invasion and GH levels. Women had longer mean follow-up (5.2 ± 3.4 years vs 3.6 ± 3.6 men, P = 0.02) and longer endpoint-free survival (P < 0.01). At last follow-up, 89.6% women and 70% men had normal IGF-1 levels (P = 0.03). Postoperative remission rates were higher in patients operated after February 15, 2011 (67.35 vs 43.5% previously, P = 0.01). In late vs early surgery group, physical changes as main indication for screening decreased (54 vs 30%, P < 0.01), while incidentaloma and hypogonadism increased. Median GH levels were lower in late vs early surgery group (P = 0.03).
CONCLUSION: We demonstrate gender-specific characteristics and an evolving spectrum of clinical presentation with implications for earlier diagnosis and personalized management of acromegaly.

Entities:  

Keywords:  Acromegaly; Gender; Growth hormone; Incidentaloma; Remission; Surgery

Mesh:

Substances:

Year:  2019        PMID: 31677093     DOI: 10.1007/s12020-019-02123-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  56 in total

1.  The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.

Authors:  Tomas Thor Agustsson; Tinna Baldvinsdottir; Jon G Jonasson; Elinborg Olafsdottir; Valgerdur Steinthorsdottir; Gunnar Sigurdsson; Arni V Thorsson; Paul V Carroll; Márta Korbonits; Rafn Benediktsson
Journal:  Eur J Endocrinol       Date:  2015-11       Impact factor: 6.664

2.  Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved.

Authors:  Yuka Kinoshita; Hiroko Fujii; Akira Takeshita; Manabu Taguchi; Megumi Miyakawa; Kenich Oyama; Shozo Yamada; Yasuhiro Takeuchi
Journal:  Eur J Endocrinol       Date:  2011-02-01       Impact factor: 6.664

3.  Symptoms and signs of acromegaly: an ongoing need to raise awareness among healthcare practitioners.

Authors:  Redzuan Zarool-Hassan; Helen M Conaglen; John V Conaglen; Marianne S Elston
Journal:  J Prim Health Care       Date:  2016-06

Review 4.  Estrogens and selective estrogen receptor modulators in acromegaly.

Authors:  Felipe H Duarte; Raquel S Jallad; Marcello D Bronstein
Journal:  Endocrine       Date:  2016-10-04       Impact factor: 3.633

5.  The metabolic profile in active acromegaly is gender-specific.

Authors:  A Ciresi; M C Amato; R Pivonello; E Nazzari; L F Grasso; F Minuto; D Ferone; A Colao; C Giordano
Journal:  J Clin Endocrinol Metab       Date:  2012-11-15       Impact factor: 5.958

6.  SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY.

Authors:  Jeremy R Anthony; Ula Abed Alwahab; Naman K Kanakiya; Diana M Pontell; Emir Veledar; Nelson M Oyesiku; Adriana G Ioachimescu
Journal:  Endocr Pract       Date:  2015-06-29       Impact factor: 3.443

7.  Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients.

Authors:  Manouchehr Shirvani; Rouzbeh Motiei-Langroudi
Journal:  World Neurosurg       Date:  2013-01-08       Impact factor: 2.104

8.  Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).

Authors:  Antonio Mestron; Susan M Webb; Ricardo Astorga; Pedro Benito; Miguel Catala; Sonia Gaztambide; Jose-Manuel Gomez; Irene Halperin; Tomas Lucas-Morante; Basilio Moreno; Gabriel Obiols; Pedro de Pablos; Concha Paramo; Antonio Pico; Elena Torres; Cesar Varela; Jose-Antonio Vazquez; Juana Zamora; Merce Albareda; Montserrat Gilabert
Journal:  Eur J Endocrinol       Date:  2004-10       Impact factor: 6.664

9.  Mortality in acromegaly: a 20-year follow-up study.

Authors:  Elina Ritvonen; Eliisa Löyttyniemi; Pia Jaatinen; Tapani Ebeling; Leena Moilanen; Pirjo Nuutila; Ritva Kauppinen-Mäkelin; Camilla Schalin-Jäntti
Journal:  Endocr Relat Cancer       Date:  2016-05-16       Impact factor: 5.678

10.  Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register.

Authors:  Christof Schöfl; Holger Franz; Martin Grussendorf; Jürgen Honegger; Cornelia Jaursch-Hancke; Bernhard Mayr; Jochen Schopohl
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

View more
  3 in total

1.  A Pituitary Society update to acromegaly management guidelines.

Authors:  Maria Fleseriu; Beverly M K Biller; Pamela U Freda; Monica R Gadelha; Andrea Giustina; Laurence Katznelson; Mark E Molitch; Susan L Samson; Christian J Strasburger; A J van der Lely; Shlomo Melmed
Journal:  Pituitary       Date:  2020-10-20       Impact factor: 4.107

Review 2.  Surgery for acromegaly: Indications and goals.

Authors:  David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-04       Impact factor: 6.055

3.  Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.

Authors:  Agnieszka Tomasik; Maria Stelmachowska-Banaś; Maria Maksymowicz; Izabella Czajka-Oraniec; Dorota Raczkiewicz; Grzegorz Zieliński; Jacek Kunicki; Wojciech Zgliczyński
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-16       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.